Skip to main content
Delfa

← Trials/Trial dossier/NCT06285448

Enrolling by invitation

Feasibility of Lecanemab Registry and Clinical Outcome Measures

Asset

Lecanemab

Listed sites

1

Recruiting sites

-

Enrollment

20

estimated

Study population

Alzheimer’s disease

Key I/E criterion

•Age ≥18

Primary endpoints

•Feasibility of enrollment•Feasibility of completing visits•Qualitative experience

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDA24-028
NCT IDNCT06285448

Timeline

Milestones

Study start2024-01-02actual
Study first posted2024-02-29actual
Last update posted2026-01-28actual
Primary completion2027-12-31estimated
Study completion2028-06-30estimated

Assets

Drug assets

Lecanemab

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•PLWD who are eligible to receive Lecanemab infusion at our clinics.
•Care Partner who provides care for the PLWD who are eligible to receive Lecanemab infusion at our clinics.
•Age >=18 years for PLWD and their care partners
•Provides informed consent prior to participation

Exclusion criteria

•Unable to read and speak English

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
2
Other (unclassified)
2

Other clinical outcomes

2 endpoints
Primary/protocol endpoint

Feasibility of enrollment

Time frame:2 years

event count, event

Primary/protocol endpoint

Feasibility of completing visits

Time frame:3 months

event count, event

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

Qualitative experience at 3 months

Time frame:3 months

descriptive

Primary/protocol endpoint/low confidence

Qualitative experience at 12 months

Time frame:12 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.